Pharmacology and Therapeutics
Methotrexate for treatment of atopic dermatitis in children and adolescents
Article first published online: 6 MAR 2014
© 2014 The International Society of Dermatology
International Journal of Dermatology
Volume 53, Issue 8, pages 1037–1041, August 2014
How to Cite
Deo, M., Yung, A., Hill, S. and Rademaker, M. (2014), Methotrexate for treatment of atopic dermatitis in children and adolescents. International Journal of Dermatology, 53: 1037–1041. doi: 10.1111/ijd.12314
- Issue published online: 14 JUL 2014
- Article first published online: 6 MAR 2014
Low-dose methotrexate is becoming established as a second-line treatment for atopic eczema in the adult population, but there has been a paucity of data to support its use for this indication in the pediatric population.
A retrospective review was undertaken of patients aged 18 years and under started on methotrexate between January 2005 and April 2010, at a hospital-based dermatology department in New Zealand.
Thirty-one patients (17 females, mean age 10 years, range 3–18 years) were reviewed. Methotrexate was found to be effective or very effective in 75% and ineffective in 25%. The mean duration of treatment for those who responded to methotrexate was 14 months (range 2–38 months), 74% of patients were still on treatment at the time of last review. The most common adverse effect was minor nausea in four patients (14%) and non-significant elevation of liver enzymes (four patients). No serious adverse effects were noted.
In our experience, methotrexate has a good safety/tolerability profile when used in low dose for the treatment of atopic dermatitis in children and adolescents and appears to be effective. Formal comparative studies are needed.